Biotech 2003 Life Sciences: Revaluation and Restructuring. The Essential Life Sciences Information Source

As a CEO, you know that making the right decision depends on having the right information, especially in the ultafast-moving world of life sciences. Facts, insight, analysis—it is crucial that you have access to the highest quality data available, and that you have it immediately. Which is why you need the definitive single-volume life sciences industry overview for chief executives, Burrill & Company's Biotech 2003 Life Sciences: Revaluation and Restructuring.
 

Know Where You Stand
Gauging your competitive position in the life sciences industry is achieved by knowing revenue figures and market caps of your chief rivals, news on clinical trials, FDA approval status, patent expiration and emerging fields of study. Biotech 2003 Life Sciences: Revaluation and Restructuring is the one comprehensive resource for all of this information. Biotech 2003 Life Sciences: Revaluation and Restructuring provides the deep knowledge and historical perspective gained from a three-decade presence in the business. It's the definitive resource for determining exactly where you stand in the biotech industry.

Biotech Business Intelligence

Organized and formatted for quick
consultation—Biotech 2003 Life Sciences:
Revaluation and Restructuring puts everything you need at your fingertips:

  • Quantitative data clearly presented in graphs, tables and charts
     
  • Insightful qualitative analysis from the industry’s thought leaders
     
  • Authoritative industry intelligence and insider perspective
     

"The best single source of comprehensive data and industry statistics. A must-have."

Dr. George Poste
CEO
Health Technology Networks


US BIOTECH MARKET CAR DECEMBER 31, 2002

ANALYSIS OF LICENCING TRENDS FOR APPROVED

US BIOTECH INDUSTRY FINANCING